Patellofemoral pain is common in young and active populations^[@bibr25-2325967119854192]^ and presents a challenge to treating health care providers owing to persistence of symptoms over time.^[@bibr17-2325967119854192]^ Patients with anterior knee pain often exhibit muscle weakness, arthrogenic muscle inhibition of the quadriceps, reduced physical activity levels, altered gait mechanics, and poor patient-reported outcomes, including quality of life.^[@bibr9-2325967119854192],[@bibr10-2325967119854192],[@bibr12-2325967119854192],[@bibr14-2325967119854192],[@bibr19-2325967119854192]^ Surgical management options are limited in this patient population; therefore, the focus for treatments is on conservative management such as physical therapy.

Among the more commonly used therapies for treating nonosteoarthritic patellofemoral pain are rest, exercise, physical therapy, and oral analgesics; however, evidence is limited to support the long-term efficacy of these interventions.^[@bibr6-2325967119854192]^ Physical therapy interventions that focus on hip and thigh muscle strengthening and pain control treatments have shown the most promise to alleviate symptoms and improve outcomes in patients with patellofemoral joint pain.^[@bibr9-2325967119854192]^ When conservative therapies fail, there are few nonsurgical options for patients with persistent anterior knee pain,^[@bibr22-2325967119854192]^ thereby making this diagnosis particularly challenging for both the treating clinician and patient. Corticosteroid injections may provide an alternative to operative care in patients with persistent pain. However, the use of such injections is usually limited owing to conflicting outcome studies, short-term efficacy, and concerns for steroid-related cartilage damage,^[@bibr29-2325967119854192]^ which is concerning for younger patients.

Hyaluronic acid (HA) is an injectable device that has been used for the treatment of tibiofemoral^[@bibr28-2325967119854192]^ and patellofemoral joint^[@bibr5-2325967119854192]^ osteoarthritis. HA injections have been proposed to provide pain relief, stimulate existing synovial fibroblasts to produce native synovial fluid, and provide cushioning and lubrication to joint surfaces.^[@bibr18-2325967119854192]^ HA has also been found to affect joint nociceptive response,^[@bibr18-2325967119854192]^ thereby interfering with reflex muscle inhibition in the quadriceps. Therefore, for patients with rehabilitation-resistant, nonosteoarthritic, chronic patellofemoral joint pain, we hypothesized that HA may provide a suitable nonoperative therapy to reduce pain and improve muscle strength and function, thereby promoting long-term joint health and muscle function.

There are currently no clinical trials studying patient-reported or strength outcomes in patients with patellofemoral pain treated with HA. Therefore, the purpose of this study was to determine the clinical efficacy of a single-dose HA injection for the treatment of chronic patellofemoral pain. The primary aim of this study was to compare anterior knee pain rating during single-legged squat, patient-reported outcomes, and quadriceps function in patients treated with a single dose of HA versus those receiving a sham injection. We compared patient-reported outcomes and quadriceps muscle function between groups at 1, 3, and 6 months following injection. We hypothesized that a single injection with HA would reduce pain, improve patient-reported function, and improve muscle strength and activation in patients who had previously failed conservative management when compared with a sham injection treatment.

Methods {#section1-2325967119854192}
=======

This was a prospective, randomized, double-blind, sham-controlled, parallel-group clinical trial to compare outcomes for 6 months after a single injection of HA in the knees of patients diagnosed with patellofemoral pain. All participants read and signed an informed consent agreement that was approved by our university's institutional review board for health sciences research. This was an investigator-initiated clinical trial with an investigational device exemption approved by the US Food and Drug Administration for off-label use of HA in the absence of arthritis and for the patellofemoral joint.

A total of 107 patients were screened for enrollment. Of these, 21 patients did not meet all inclusion and exclusion criteria and were excluded; therefore, 86 patients were enrolled and randomized (65 females, 21 males; mean ± SD age, 27.0 ± 7.7 years; height, 168.6 ± 8.9 cm; weight, 74.6 ± 17.0 kg; body mass index, 26.2 ± 5.2) ([Table 1](#table1-2325967119854192){ref-type="table"}). A flowchart of patient selection is shown in [Figure 1](#fig1-2325967119854192){ref-type="fig"}. Patients qualified if they were 15 to 45 years old, with a history and clinical diagnosis of anterior knee pain for longer than 3 months, pain and crepitus with patellar grind, 4 or greater pain ratings (out of 10), and a minimum of 4 weeks of failed physical therapy. Patients were excluded if they had any of the following: joint effusion, patellar maltracking or instability, patellar tendinitis, any evidence of tibiofemoral or patellofemoral joint space narrowing or osteoarthritis (defined as greater than grade II Kellgren-Lawrence rating) confirmed on radiographs at the time of enrollment, any indications for arthroscopy (eg, meniscus tear or instability), prior steroid injection within 6 months, any prior use of viscosupplementation, allergy to avian products, body mass index \>40, prior knee surgery, evidence of hip injury, inflammatory arthritis, or other comorbid or known psychiatric conditions. Patients refrained from any treatments outside the clinical trial, including pain medication other than acetaminophen for the duration of the study.

###### 

Patient Demographics by Group Membership*^a^*

![](10.1177_2325967119854192-table1)

                                       HA Injection   Sham Injection   Combined      *P*
  ------------------------------------ -------------- ---------------- ------------- -----
  Age, y                               26.0 ± 7.0     28.1 ± 8.4       27.0 ± 7.7    .24
  Height, cm                           168.9 ± 9.2    168.3 ± 8.6      168.6 ± 8.9   .66
  Mass, kg                             75.7 ± 16.6    73.5 ± 17.6      74.6 ± 17.0   .59
  BMI                                  26.4 ± 5.3     25.8 ± 5.1       26.1 ± 5.2    .62
  Injection side, right:left:both, n   17:24:4        21:14:6          38:38:10      .19

*^a^*Values are expressed as mean ± SD unless otherwise indicated. BMI, body mass index; HA, hyaluronic acid.

![CONSORT (Consolidated Standards of Reporting Trials) flowchart. BMI, body mass index; HA, hyaluronic acid; KL, Kellgren-Lawrence.](10.1177_2325967119854192-fig1){#fig1-2325967119854192}

After screening, eligible patients completed baseline assessments for all outcome measures. The outcome assessments included patellofemoral pain assessment per a visual analog scale (VAS) during a single-legged squat, composite Knee injury and Osteoarthritis Outcome Score (KOOS; sum of all subdomain scores), Kujala patellofemoral pain questionnaire, and Tegner activity rating. Body mass--normalized isometric maximal voluntary knee extension contraction torque and quadriceps central activation ratio were measured with the knee flexed to 60° in a multimode dynamometer (System 3; Biodex Inc) and according to previously published methods.^[@bibr16-2325967119854192]^

A sealed envelope containing group assignment from a random number generator was opened just prior to injection. Patients were randomly assigned (in 1:1 ratio) to receive either an injection of 6 mL of HA (Synvisc-One; Sanofi-Aventis Inc) or a sham injection (needle stick). To maintain blinding, patients lay supine on a treatment table with a screen that shielded their view of the knee injection. Under a sterile technique, a 21-gauge needle was carefully inserted into the intra-articular space via a superolateral approach. Based on the randomization, either 6 mL of HA was injected, or the needle was left in place and removed for a similar length of time to simulate injection.

Each patient was given instructions to perform home stretching and strengthening exercises 4 times per week for the first month postinjection ([Table 2](#table2-2325967119854192){ref-type="table"}). Patients returned at 1, 3, and 6 months for repeat outcomes assessment with a blinded observer using the same procedures as in the baseline assessment. Group assignment was revealed to the patients after the 6-month outcome assessment, and a crossover treatment (single injection of 6 mL of HA with the same technique described earlier) was offered to patients receiving the sham injection who were still symptomatic. In patients who had bilateral qualifying knee pain, we treated both knees with the same randomized treatment as before.

###### 

Home Exercise Program*^a^*

![](10.1177_2325967119854192-table2)

  Exercise                                          Description
  ------------------------------------------------- ----------------------------------
  Quadriceps sets                                   10-s hold × 20 repetitions
  Straight-legged raises (hip flexion)              1- to 2-s hold × 20 repetitions
  Side-lying hip abduction                          1- to 2-s hold × 20 repetitions
  Seated isometric hamstring contractions           10 s × 10 repetitions
  Standing calf raises                              1- to 2-s hold × 20 repetitions
  Prone bent knee hip adduction                     10-s hold × 20 repetitions
  Static stretching (calf, hamstring, quadriceps)   20- to 25-s hold × 3 repetitions

*^a^*Patients were instructed to complete 4 times per week for the first 4 weeks postinjection.

Sample size was calculated with published data reporting changes in VAS pain scores in patients with patellofemoral pain after an exercise intervention.^[@bibr1-2325967119854192]^ Given the variability in VAS scores, we determined that 100 patients (50 per group) would be sufficient to detect a 1.0-point difference in VAS scores between treatment groups at the 6-month time point. This estimate assumes 80% power and an alpha level of .05. This sample size accounts for 10% attrition rate. We performed an interim power analysis based on variability in pain scores from the first 76 patients (34 sham, 42 HA injection) who had completed the study. We decided to stop enrollment early (N = 86) owing to low statistical power (ie, futility) and to proceed with full statistical analyses.

Statistical Analyses {#section2-2325967119854192}
--------------------

Linear mixed analysis of covariance (ANCOVA) models---for nonequally spaced repeated measures---were constructed to compare the distributions of the primary and secondary outcome variables between the 2 clinical trial arms (ie, HA injected and sham). All ANCOVAs were conducted under the guidelines of the intent-to-treat principle.

###  {#section9-2325967119854192}

#### ANCOVA Model Specification {#section3-2325967119854192}

For each ANCOVA, the data of the response variable represented the 1-, 3-, and 6-month postbaseline changes in the outcome variable, and the independent variables identified the clinical trial arm of randomization (HA injected or sham) and the postbaseline assessment time (1, 3, or 6 months). The preintervention measurements of the outcome variable (eg, VAS score) served as the ANCOVA covariate so that all of the between-arm comparisons could be adjusted to reflect a between--clinical arm comparison between 2 groups of participants who started the intervention period at a common baseline outcome value.

#### Hypothesis Testing {#section4-2325967119854192}

With regard to hypothesis testing, a traditional hierarchical hypothesis testing approach was utilized. Type III *F* tests were first conducted to test for "clinical arm" and "postbaseline assessment time" main effects and "clinical arm" by "postbaseline assessment time" interaction. A *P* ≤ .05 null hypothesis decision rule was established a priori as the null hypothesis rejection criterion for all ANCOVA type III *F* tests. Linear contrasts of the ANCOVA least square means were constructed to derive the 2-sample *t* tests for comparing the mean 1-, 3-, and 6-month postbaseline changes in the outcome variable between the 2 clinical arms. A Bonferroni-corrected *P* ≤ .05 null hypothesis decision rule was established a priori as the null hypothesis rejection criterion for the 1-, 3-, and 6-month between-arm comparisons of the postbaseline mean change in the outcome variable.

Results {#section5-2325967119854192}
=======

Between March 2010 and April 2016, a total of 86 patients provided consent and were enrolled, including 45 patients randomized to HA injection (34 females, 11 males) and 41 to sham (31 females, 10 males). Six patients were lost to follow-up (3 HA injection, 3 sham injection; 93% follow-up rate) ([Figure 1](#fig1-2325967119854192){ref-type="fig"}). There were no significant group differences in patient characteristics ([Table 1](#table1-2325967119854192){ref-type="table"}). For our primary outcome measure of VAS pain, there was a main effect for time (*P* = .005) but no group interaction (*P* = .451). There were no significant group × time interactions for any of the other analyzed outcome measures ([Figure 2](#fig2-2325967119854192){ref-type="fig"}). Specifically, there were no significant between-intervention differences (HA injected vs sham) in the 1-, 3-, or 6-month changes in outcome scores, patient-reported function, muscle strength, or activation from at baseline.

![Between-group comparisons of anterior knee pain during single-legged squat, Kujala score, Tegner activity rating, Knee injury and Osteoarthritis Outcome Score, normalized maximal voluntary knee extension torque, and central activation ratio, measured at baseline and at 1, 3, and 6 months postrandomization. Values are presented as mean ± SD. VAS, visual analog scale.](10.1177_2325967119854192-fig2){#fig2-2325967119854192}

Discussion {#section6-2325967119854192}
==========

This is the first study to compare patient-reported outcomes, pain, muscle strength, and activation in patients with patellofemoral pain, without a radiographic diagnosis of patellofemoral osteoarthritis, who were treated with a single dose of HA. The study provides evidence that HA does not affect pain, patient-reported outcomes, or muscle function beyond the effect of sham intervention and home exercises in a 6-month follow-up period for patients with patellofemoral pain. Prior clinical trials^[@bibr3-2325967119854192],[@bibr4-2325967119854192],[@bibr15-2325967119854192]^ studying outcomes following HA injections for chronic osteoarthritic knee pain have had conflicting results, suggesting that HA has a varying effect in patient populations. In the current study, patients were free from osteoarthritis diagnosis and had failed to improve after 1 month of conservative treatment. The time effect for the primary outcome variable suggests that VAS pain scores measured during a single-legged squat were reduced, on average across groups, over the 6-month treatment period. The magnitude of pain reduction experienced in patients enrolled in the current study may be clinically relevant; however, factors other than HA injection likely played a role in any observed changes in pain rating.

Nonsurgical management of anterior knee pain is an area for extensive research given the recurrent and persistent nature of the complaint. In a prior review,^[@bibr9-2325967119854192]^ short-term pain reductions in patients with anterior knee pain were observed across multiple studies of clinical hip and/or quadriceps muscle strengthening. Outcomes in patients with patellofemoral pain tended to deteriorate with mid- and long-term follow-up, suggesting that patellofemoral pain is recurrent and may require longer-term interventions to maintain muscle strength and function.^[@bibr20-2325967119854192],[@bibr24-2325967119854192]^ These findings agree with those reported in the current study, where the sharpest reduction in VAS pain was observed in the first month, when patients were actively engaged in home muscle activation exercises.

HA injections have been studied extensively in patients with osteoarthritis. Serum and synovial biomarker changes in patients with arthroscopically diagnosed chondromalacia patella are similar to those with early-stage cartilage changes associated with osteoarthritis.^[@bibr27-2325967119854192]^ Pain reduction has been reported in patients with patellofemoral osteoarthritis after a 3-injection series of HA.^[@bibr7-2325967119854192]^ HA was also reported to be effective in reducing pain in young, active patients with patellofemoral or tibiofemoral chondropathies; however, that study was not a controlled trial.^[@bibr26-2325967119854192]^ The current study reports reduced pain levels over time in all patients but no differences between treatment groups. Our study was controlled by a sham injection---that is, a simple needle stick under sterile conditions. Prior studies comparing intra-articular injection efficacy were controlled by a saline placebo injection. Saline placebo injections have been proven to effectively reduce knee pain^[@bibr23-2325967119854192]^; therefore, we selected a sham control to avoid confounding because of a potential placebo effect.

The home exercise program used in the current study was not progressive, so it is not surprising that we did not observe changes in knee extension strength or central activation over time. Strength and central activation ratio have been found to be reliable over time in patients with patellofemoral pain^[@bibr21-2325967119854192]^; therefore, we are confident in this outcome measure. The patients in the current study were enrolled after a failed course of conservative management, so the exercise program was designed to determine whether the addition of an intra-articular injection of HA could supplement the potential benefits of exercise. A similar exercise program was utilized in a small clinical trial^[@bibr13-2325967119854192]^ for patients with muscle weakness following knee ligament reconstructions. That study combined both supervised and home-based exercises and was found that exercise increased knee extension strength. Future studies may evaluate different forms of therapy in conjunction with intra-articular therapies in patients with chronic patellofemoral pain.

Limitations {#section7-2325967119854192}
-----------

The current study population was majority female. This is expected since anterior knee pain affects females more than males. The study enrollment was stopped prematurely on the basis of an interim power analysis demonstrating that several hundred patients (272 per clinical arm) would be needed to achieve an acceptable level of statistical power (ie, 0.80 or greater) for the VAS postbaseline change between clinical arms. Therefore, we decided to stop enrollment and perform statistical analyses. The results of this study suggest that there is no clinically meaningful effect of intra-articular injections on pain or muscle-related outcomes in patients with patellofemoral pain. Because we did stop early and thus had fewer patients, there is a possibility of type II error. Another limitation is the possibility that 1 month of conservative management was not enough time to be considered a failed attempt at treatment, although prior studies have found large-magnitude effects in reducing patellofemoral pain after a monthlong or less rehabilitation intervention.^[@bibr8-2325967119854192],[@bibr11-2325967119854192]^ Challenges with blinding may have also confounded patient reports, as patients may have been able to tell the difference between a sham and HA injection. We purposefully chose not to control with a saline injection given the potential effect that has been reported.^[@bibr2-2325967119854192]^ Finally, during patient screening, we used radiographs, not magnetic resonance imaging, to rule out knee osteoarthritis.

Conclusion {#section8-2325967119854192}
==========

We observed improvements in both groups for patient-reported pain and function, with no change in quadriceps strength or activity rating. We observed no differences between groups, meaning that HA injection had no effect on pain or functional outcomes in patients with patellofemoral pain. Therefore, the use of an HA injection within this population should be utilized with caution.
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